https://www.nhs.uk/conditions/medical-cannabis/<\/a>.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1533", "label" : {"_value" : "Biography information for Dame Diana Johnson"}
}
, "answeringMemberConstituency" : {"_value" : "Kingston upon Hull North and Cottingham"}
, "answeringMemberPrinted" : {"_value" : "Dame Diana Johnson"}
, "dateOfAnswer" : {"_value" : "2024-10-14", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-10-14T11:40:44.33Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "1"}
, "answeringDeptShortName" : {"_value" : "Home Office"}
, "answeringDeptSortName" : {"_value" : "Home Office"}
, "date" : {"_value" : "2024-10-04", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for the Home Department, what steps she is taking to help ensure police officers are trained to deal appropriately with people who rely on prescribed medical cannabis.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : "http://data.parliament.uk/members/5307", "tablingMemberConstituency" : {"_value" : "Worthing West"}
, "tablingMemberPrinted" : [{"_value" : "Dr Beccy Cooper"}
], "uin" : "7267"}
, {"_about" : "http://data.parliament.uk/resources/1689862", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1689862/answer", "answerText" : {"_value" : "The Department does not hold details relating to the age of people prescribed medicinal cannabis.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-02-27", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-02-27T11:18:22.867Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-02-19", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, how many people aged under 18 have been prescribed medicinal cannabis as of 19 February 2024.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "14583"}
, {"_about" : "http://data.parliament.uk/resources/1689392", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1689392/answer", "answerText" : {"_value" : "
Licensed cannabis-based medicines are routinely available on the National Health Service. However, clinical guidelines from the National Institute for Health and Care Excellence (NICE) demonstrate a clear need for more evidence to support routine prescribing and funding decisions for unlicensed cannabis-based medicines.<\/p>
<\/p>
The Government continues to call on manufacturers to invest in research and clinical trials to prove if their products are safe and effective and offers scientific and research advice from the Medicines and Healthcare products Regulatory Agency and the NICE.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-02-21", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-02-21T09:43:53.517Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-02-16", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what plans her Department has to make medicinal cannabis more accessible to those who need it.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4828", "label" : {"_value" : "Biography information for Paula Barker"}
}
, "tablingMemberConstituency" : {"_value" : "Liverpool, Wavertree"}
, "tablingMemberPrinted" : [{"_value" : "Paula Barker"}
], "uin" : "14291"}
, {"_about" : "http://data.parliament.uk/resources/1687065", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1687065/answer", "answerText" : {"_value" : "
The Department, via the National Institute for Health and Care Research (NIHR), is developing a programme of two randomised controlled trials to test the safety and efficacy of medicinal cannabis products to treat epilepsy in adults and children. The trials will start as soon as possible, and the results will be published once the trials have completed and the findings peer reviewed.<\/p>
<\/p>
Furthermore, the Government continues to encourage manufacturers to invest in research and has highlighted that public funding is available for high quality applications. The Medicines and Healthcare products Regulatory Agency and the NIHR can provide applicants with scientific and research advice.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-02-09", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-02-09T10:47:53.36Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-02-02", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what progress she has made with (a) regulatory, (b) research and (c) NHS partners on establishing clinical trials to test the (i) safety and (ii) efficacy of medical cannabis products.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4995", "label" : {"_value" : "Biography information for Sarah Dyke"}
}
, "tablingMemberConstituency" : {"_value" : "Somerton and Frome"}
, "tablingMemberPrinted" : [{"_value" : "Sarah Dyke"}
], "uin" : "12872"}
, {"_about" : "http://data.parliament.uk/resources/1682606", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1682606/answer", "answerText" : {"_value" : "
Licensed cannabis-based medicines, that have been proved effective in clinical trials and judged cost-effective by the National Institute of Health and Care Excellence (NICE), are routinely available on the National Health Service, including for people aged over two years old with certain types of epilepsy. However, clinical guidelines from NICE demonstrate a clear need for more evidence to support routine prescribing and funding decisions for unlicensed cannabis-based medicines.<\/p>
We continue to call on manufacturers to conduct research to prove if their products are safe and effective and we are working with regulatory, research and NHS partners to establish clinical trials to test the safety and efficacy of these products.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-01-22", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-01-22T14:04:14.56Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-01-16", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what recent assessment she has made of the potential merits of allowing children to be issued medical cannabis prescriptions on the NHS.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4995", "label" : {"_value" : "Biography information for Sarah Dyke"}
}
, "tablingMemberConstituency" : {"_value" : "Somerton and Frome"}
, "tablingMemberPrinted" : [{"_value" : "Sarah Dyke"}
], "uin" : "9974"}
, {"_about" : "http://data.parliament.uk/resources/1681903", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1681903/answer", "answerText" : {"_value" : "
Licensed cannabis-based medicines are available and funded on the National Health Service, where the safety, quality and clinical and cost effectiveness has been assessed and approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence.<\/p>
The Government continues to encourage manufacturers to develop new treatments and invest in research and clinical trials, and offers scientific and research advice from the MHRA and the National Institute for Health and Care Research.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-01-17", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-01-17T17:12:08.693Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-01-15", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, if she will make an assessment of the effectiveness of medicinal cannabis treatments provided by the NHS; and whether she has plans to increase the number of treatments available.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1447", "label" : {"_value" : "Biography information for Andrew Rosindell"}
}
, "tablingMemberConstituency" : {"_value" : "Romford"}
, "tablingMemberPrinted" : [{"_value" : "Andrew Rosindell"}
], "uin" : "9453"}
, {"_about" : "http://data.parliament.uk/resources/1681904", "AnsweringBody" : [{"_value" : "Department for Business and Trade"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1681904/answer", "answerText" : {"_value" : "
The Department for Business and Trade (DBT) actively assists life sciences companies in their endeavours to invest, expand, and export, thereby generating employment and economic growth.<\/p>
UK-based life sciences businesses receive support from DBT through trade missions to key markets, participation in major trade events, tackling market access barriers, upskilling exporters, and guidance on entering new markets. Although routine assessments of the economic impact of specific life sciences\u2019 subsectors like medicinal cannabis are not conducted, DBT is committed to supporting companies of various sizes throughout their export and inward investment endeavours while adhering to national regulatory guidelines.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4474", "label" : {"_value" : "Biography information for Kevin Hollinrake"}
}
, "answeringMemberConstituency" : {"_value" : "Thirsk and Malton"}
, "answeringMemberPrinted" : {"_value" : "Kevin Hollinrake"}
, "dateOfAnswer" : {"_value" : "2024-01-23", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-01-23T17:59:05.127Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "214"}
, "answeringDeptShortName" : {"_value" : "Business and Trade"}
, "answeringDeptSortName" : {"_value" : "Business and Trade"}
, "date" : {"_value" : "2024-01-15", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State of Business and Trade, what estimate she has made of the contribution of domestic medicinal cannabis production to the economy.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1447", "label" : {"_value" : "Biography information for Andrew Rosindell"}
}
, "tablingMemberConstituency" : {"_value" : "Romford"}
, "tablingMemberPrinted" : [{"_value" : "Andrew Rosindell"}
], "uin" : "9454"}
, {"_about" : "http://data.parliament.uk/resources/1663633", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1663633/answer", "answerText" : {"_value" : "
Licensed cannabis-based medicines are routinely available on the National Health Service. However, clinical guidelines from the National Institute for Health and Care Excellence demonstrate a clear need for more evidence to support routine prescribing and funding decisions for unlicensed cannabis-based medicines.<\/p>
Funding of unlicensed products is subject to local National Health Service decisions on a case-by-case basis. These decisions follow clearly developed procedures that ensure equitable distribution of funding, prioritising those medicines that have proved their safety, quality, and clinical and cost effectiveness.<\/p>
We continue to call on manufacturers to conduct research to prove if their products are safe and effective and we are working with regulatory, research and NHS partners to establish clinical trials to test the safety and efficacy of these products.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"}
}
, "answeringMemberConstituency" : {"_value" : "Colchester"}
, "answeringMemberPrinted" : {"_value" : "Will Quince"}
, "dateOfAnswer" : {"_value" : "2023-10-19", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2023-10-19T14:43:27.227Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2023-10-13", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, whether the Government is taking steps to reduce inequalities in access to medicinal cannabis prescribed under the NHS.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4079", "label" : {"_value" : "Biography information for Julian Sturdy"}
}
, "tablingMemberConstituency" : {"_value" : "York Outer"}
, "tablingMemberPrinted" : [{"_value" : "Julian Sturdy"}
], "uin" : "201487"}
, {"_about" : "http://data.parliament.uk/resources/1663778", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1663778/answer", "answerText" : {"_value" : "
Licensed cannabis-based medicines are routinely available on the National Health Service. However, clinical guidelines from the National Institute for Health and Care Excellence demonstrate a clear need for more evidence to support routine prescribing and funding decisions for unlicensed cannabis-based medicines.<\/p>
Funding of unlicensed products is subject to local NHS decisions on a case-by-case basis. These decisions follow clearly developed procedures that ensure equitable distribution of funding, prioritising those medicines that have proved their safety, quality and clinical and cost effectiveness.<\/p>
We continue to call on manufacturers to conduct research to prove if their products are safe and effective and we are working with regulatory, research and NHS partners to establish clinical trials to test the safety and efficacy of these products.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"}
}
, "answeringMemberConstituency" : {"_value" : "Colchester"}
, "answeringMemberPrinted" : {"_value" : "Will Quince"}
, "dateOfAnswer" : {"_value" : "2023-10-19", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2023-10-19T11:14:45.24Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2023-10-13", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will take steps to increase access to cannabis-based medicinal products on the NHS.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4511", "label" : {"_value" : "Biography information for Dr Rupa Huq"}
}
, "tablingMemberConstituency" : {"_value" : "Ealing Central and Acton"}
, "tablingMemberPrinted" : [{"_value" : "Dr Rupa Huq"}
], "uin" : "201631"}
], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&hansardHeading=Cannabis%3A+Medical+Treatments", "page" : 0, "startIndex" : 1, "totalResults" : 247, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}